RCS - Redx Pharma plc - Redx to Present Poster on RXC007 at ICLAF

Redx PharmaAnnouncement

29/09/2022 07:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220929:nRSc1427Ba&default-theme=true

RNS Number : 1427B  Redx Pharma plc  29 September 2022

REDX PHARMA PLC

("Redx" or "the Company")

 

Redx to Present Poster on Encouraging Preclinical Fibrosis Data for RXC007 at
the 21st International Colloquium on Lung and Airway Fibrosis

 

 

Alderley Park, 29 September 2022 Redx (AIM: REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease, today announces that it will present a poster on RXC007 at
the forthcoming 21st International Colloquium on Lung and Airway Fibrosis (1-5
October 2022, Reykjavik, Iceland/virtual).

 

The poster will present RXC007 preclinical efficacy data across fibrosis
models, and Phase 1 data for single and multiple (up to 14 days) ascending
dose studies in healthy male volunteers. RXC007, Redx's lead fibrosis asset,
is a highly selective ROCK 2 inhibitor, which is expected to enter Phase 2a
clinical studies for lead indication idiopathic pulmonary fibrosis (IPF) in
2022, following encouraging Phase 1 safety and pharmacokinetic data.

 

 Title:                       RXC007, a potent, highly selective ROCK2 inhibitor, demonstrates preclinical
                              efficacy across fibrosis models and good Phase 1 safety profile, supporting
                              development in IPF and ILD.

 Abstract number:             66
 Abstract code:               PDD-08

 Day/Date:                    Sunday, 2 October 2022

 Time:                        15:00-16:30

 Session name and category:   Posters - Drug Development

 

A copy of the poster will be made available on the Company's website following
the presentation at: https://www.redxpharma.com/scientific-publications/
(https://www.redxpharma.com/scientific-publications/)

 

 For further information, please contact:

 Redx Pharma Plc

 UK Headquarters                                             T: +44 (0)1625 469 918

 Caitlin Pearson, Head of Communications ir@redxpharma.com
 (mailto:ir@redxpharma.com)

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)                 T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                              T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                  T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                              T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase
2 programme in November 2021. The Company's selective ROCK2 inhibitor product
candidate, RXC007, is in development for idiopathic pulmonary fibrosis and
commenced a Phase 1 clinical trial in June 2021. Encouraging safety and
pharmacokinetic data has been reported, and a Phase 2 clinical program is
confirmed to start in 2022. Redx's third drug candidate, RXC008, a GI-targeted
ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is
currently in pre-IND stage, with Phase 1 clinical studies expected to commence
in 2023.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly following its
acquisition of Loxo Oncology, and RXC006, a Porcupine inhibitor targeting
fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which
AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has
forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a
preclinical pan-RAF inhibitor, which has received IND clearance from the US
FDA, and an early stage oncology research collaboration.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGLGDCCXDDGDC